0.34 to 0.74). As compared with PES, the risk of death/ myocardial infarction (MI) also tended to be lower with PEB, whereas the risk of death was significantly reduced with PEB (HR: 0.38, 95% CI: 0.17 to 0.87).
alternatives (including 2 pharmacoactive strategies that used the same drug) in this challenging anatomical scenario. This systematic long-term analysis provides robust clinical evidence further supporting the maintained safety and efficacy of PEB in patients with DES-ISR. Due to the clinical relevance of the current findings, discussing some methodological aspects would be of major interest.
First, the generalizability of the findings appears promising as exclusion criteria were very limited in this trial (5) . Second, the possibility of bias appears to be extremely low although some imprecision cannot be ruled out due to the sample size. Due to the study design, treatment allocation was not concealed but blinded outcome assessors were used. There is a possibility, however, that the indication for reinterventions at follow-up would have been influenced by their perceived risk benefit. Treating recurrent ISR in patients with a double metal layer or in those previously treated with PEB might be considered as less attractive than treating ISR after BA failure (2).
However, the magnitude of the outcome differences in favor of the 2 pharmacoactive arms dispels any potential concern in this regard (4) .
Third, as these findings do not come from the primary analysis of the trial, they should be considered exploratory in nature. Results, however, were consistent among several pre-specified clinical and angiographic subsets of interest that showed wide confidence estimates but no interaction between PEB and PES.
Fourth, regarding efficacy, TLR at 3 years occurred in 33.3% of cases treated with PEB and in 24.2% of those treated with PES. Although this numeric difference was not statistically significant, the trend (p ¼ 0.11) in favor of PES may be a cause for concern. Whether this represents a chance finding or rather a real signal of reduced relative efficacy remains to be determined. that the occurrence of angiographic ISR has prognostic value even in asymptomatic patients (14) . A large study, also from the Munich group, (including w10,000 patients with w15,000 treated lesions) suggested that the presence of ISR during late angiographic surveillance was an independent predictor of 4-year mortality after adjusting for classical clinical and angiographic factors (14) .
